The Department of Veterans Affairs (VA) Veterans Health Administration awarded a single-award indefinite delivery contract to Cardinal Health 414, LLC, a subsidiary of Cardinal Health, Inc., to provide a range of general radiopharmaceutical products and services. The $6.9 million IDV, which has a base period of performance from August 1, 2023 through July 31, 2028, allows for the ongoing supply of radiopharmaceuticals, radioactive isotopes, diagnostic imaging agents, and specialty pharmaceuticals to support nuclear medicine procedures at VA medical facilities nationwide.
Under this contract, Cardinal Health 414 will fulfill both scheduled and emergency deliveries of products such as technetium-99m, iodine-123, iodine-131, indium-111, thallium-201, fluorine-18 FDG, and gallium-67. The company will also provide radiopharmaceutical therapies, quality control testing, regulatory compliance, and consultation services. The contract scope includes deliveries to various VA Integrated Service Networks, with a $1.35 million task order covering the North Texas region through 2025. Cardinal Health 414, as a major supplier to federal healthcare agencies, holds multiple other IDVs with the VA, Department of Defense, and National Institutes of Health to support their respective nuclear medicine programs.
Generated 9/7/24, 9:40 AM